A myeloid–stromal niche and gp130 rescue in NOD2-driven Crohn’s disease

Shikha Nayar, Joshua K. Morrison, Mamta Giri, Kyle Gettler, Ling-shiang Chuang, Laura A. Walker, Huaibin M. Ko, Ephraim Kenigsberg, Subra Kugathasan, Miriam Merad, Jaime Chu and Judy H. Cho ()
Additional contact information
Shikha Nayar: Icahn School of Medicine at Mount Sinai
Joshua K. Morrison: Icahn School of Medicine at Mount Sinai
Mamta Giri: Icahn School of Medicine at Mount Sinai
Kyle Gettler: Icahn School of Medicine at Mount Sinai
Ling-shiang Chuang: Icahn School of Medicine at Mount Sinai
Laura A. Walker: Icahn School of Medicine at Mount Sinai
Huaibin M. Ko: The Mount Sinai Hospital
Ephraim Kenigsberg: Icahn School of Medicine at Mount Sinai
Subra Kugathasan: Emory University
Miriam Merad: Icahn School of Medicine at Mount Sinai
Jaime Chu: Icahn School of Medicine at Mount Sinai
Judy H. Cho: Icahn School of Medicine at Mount Sinai

Nature, 2021, vol. 593, issue 7858, 275-281

Abstract: Abstract Crohn’s disease is a chronic inflammatory intestinal disease that is frequently accompanied by aberrant healing and stricturing complications. Crosstalk between activated myeloid and stromal cells is critical in the pathogenicity of Crohn’s disease1,2, and increases in intravasating monocytes are correlated with a lack of response to anti-TNF treatment3. The risk alleles with the highest effect on Crohn’s disease are loss-of-function mutations in NOD24,5, which increase the risk of stricturing6. However, the mechanisms that underlie pathogenicity driven by NOD2 mutations and the pathways that might rescue a lack of response to anti-TNF treatment remain largely uncharacterized. Here we use direct ex vivo analyses of patients who carry risk alleles of NOD2 to show that loss of NOD2 leads to dysregulated homeostasis of activated fibroblasts and macrophages. CD14+ peripheral blood mononuclear cells from carriers of NOD2 risk alleles produce cells that express high levels of collagen, and elevation of conserved signatures is observed in nod2-deficient zebrafish models of intestinal injury. The enrichment of STAT3 regulation and gp130 ligands in activated fibroblasts and macrophages suggested that gp130 blockade might rescue the activated program in NOD2-deficient cells. We show that post-treatment induction of the STAT3 pathway is correlated with a lack of response to anti-TNF treatment in patients, and demonstrate in vivo in zebrafish the amelioration of the activated myeloid–stromal niche using the specific gp130 inhibitor bazedoxifene. Our results provide insights into NOD2-driven fibrosis in Crohn’s disease, and suggest that gp130 blockade may benefit some patients with Crohn’s disease—potentially as a complement to anti-TNF therapy.

Date: 2021
References: Add references at CitEc
Citations: View citations in EconPapers (4)

Downloads: (external link)
https://www.nature.com/articles/s41586-021-03484-5 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:593:y:2021:i:7858:d:10.1038_s41586-021-03484-5

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/s41586-021-03484-5

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().